HyperBio Therapeutics ApS: Financial statements 2022
CVR: 41244909
Source: annual report 2022, Danish Business Authority
01/01/2022 – 31/12/2022
HyperBio Therapeutics ApS (CVR 41244909) has filed annual accounts for 2022. In 2022, the company reported a gross profit of DKK -8,628,935 and a net result of DKK -7,656,366 compared with DKK -10,612,873 the year before. Equity in the 2022 report amounted to DKK -2,287,469.
- Gross Profit
- DKK -8,628,935
- Profit/Loss
- DKK -7,656,366
- Equity
- DKK -2,287,469
- Total Assets
- DKK 15,671,741
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2022 | - | -8.6 mio. | -7.7 mio. | -2.3 mio. | - |
| 2021 | - | -12.9 mio. | -10.6 mio. | 5.4 mio. | - |
Official annual report
Keep an eye on HyperBio Therapeutics ApS
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2022
HyperBio Therapeutics ApS has published its annual report for 2021. Gross profit came to DKK -12,881,904, and the net result was DKK -10,612,873.
About HyperBio Therapeutics ApS
HyperBio Therapeutics ApS was a Danish company of the type Anpartsselskab based in Vejle Øst, founded in 2020. The company has been dissolved on 14 January 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. In 2023, the company reported a gross profit of DKK -74,484 and a net result of DKK -972,747 compared with DKK -7,656,366 the year before. Equity in the 2023 report amounted to DKK 739,784.